Invesco
HOWL icon

Invesco’s Werewolf Therapeutics HOWL Stock Holding History

Invesco’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-14,232
Closed -$13.8K – 3800
2025
Q1 		$13.8K Sell
14,232
-357
-2% -$467 ﹤0.01% 3753
2024
Q4 		$21.6K Buy
14,589
+953
+7% +$1.94K ﹤0.01% 3739
2024
Q3 		$28.9K Sell
13,636
-392
-3% -$892 ﹤0.01% 3728
2024
Q2 		$34.2K Buy
+14,028
New +$67.4K ﹤0.01% 3854

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Invesco's HOWL Position: Q2 2025 in Review

Invesco sold out of Werewolf Therapeutics (HOWL) in Q2 2025, closing a stake of 14,232 shares — an estimated $13.8K sold.

Invesco first reported a position in HOWL in Q2 2024 and held it in 4 quarters. The position peaked at $34.2K in Q2 2024. 65 funds tracked by Wall St. Rank hold HOWL as of Q2 2025.

  • Invesco reported no remaining Werewolf Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Invesco sold 14,232 Werewolf Therapeutics shares in Q2 2025, an estimated $13.8K.
  • Invesco first reported a position in Werewolf Therapeutics in Q2 2024 and held it in 4 quarters.
  • Invesco's Werewolf Therapeutics position peaked at $34.2K in Q2 2024.
  • 65 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q2 2025.

Based on Invesco's 13F filing for Q2 2025, filed 13 Aug 2025.